Gene editing for hypercholesterolemia: From scientific breakthrough to therapeutic frontier

Hypercholesterolemia remains a major global contributor to atherosclerotic cardiovascular disease, despite decades of pharmacological management with statins and PCSK9 inhibitors. Recent advances in gene editing, particularly CRISPR/Cas9-based strategies, are now redefining the therapeutic landscape. This review outlines the evolution of liver-directed gene editing, from early adenoviral vectors to the latest generation of GalNAc-conjugated lipid nanoparticles capable of delivering gene editors directly to hepatocytes with high specificity and safety.

Preclinical studies in mice have demonstrated the efficacy of targeting key genes such as PCSK9, ANGPTL3, and APOC3 to achieve sustained reductions in plasma LDL-cholesterol—up to 60%—with durable effects and minimal liver toxicity. The most striking results come from nanoparticle-mediated delivery of CRISPR base editors, which enable precise and permanent modifications to pathogenic alleles. Data from non-human primate models further reinforce translational potential, showing robust LDL-cholesterol lowering and long-term safety in rhesus macaques and cynomolgus monkeys.

Clinical trials are now underway, with companies like Verve Therapeutics testing single-dose gene-editing therapies (e.g., VERVE-101) in patients with familial hypercholesterolemia. The scope of targets is expanding beyond PCSK9 to include other regulators of lipid metabolism, highlighting the flexibility of this technology. However, ethical, regulatory, and cost considerations remain central to future adoption. Public perception and careful selection of high-risk populations will shape its integration into standard care.

Gene editing for dyslipidemia is no longer theoretical—it is on the threshold of becoming a transformative tool in cardiovascular prevention. Understanding its implications is key to navigating a new era in lipid management and personalized medicine.